Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME-344 plus Topotecan in Solid Tumors
NCT02100007Phase 2Terminated
- Sponsor
- MEI Pharma
- Start
- Apr 2014
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of ME-344 in small cell lung cancer (SCLC), ovarian cancer, Cervical Cancer (CC), sponsored by MEI Pharma. Started Apr 2014; status: terminated.
02
Drugs
ME-344
03
Conditions
small cell lung cancer (SCLC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT02100007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100007.